Full wire
Times are UTC. Priority tells you how much a story changes things. What the levels mean
Corxel Pharmaceuticals and Amanat Acquisition Corp signed a business combination agreement expected to bring about $377 million before costs, to fund a global phase 3 obesity programme for the oral GLP 1 drug CX11.
BERKELEY HEIGHTS, NJ · Corxel and Amanat Acquisition Corp joint press release, 26 Oct 2026, filed with the SEC as Exhibit 99.1 to Amanat Form 8-K
Lilly says the top EloraTZP pairing produced 23.3% average weight loss at 48 weeks in adults with obesity and type 2 diabetes, against 14.8% on tirzepatide alone. Dropouts for side effects were higher with the combination.
INDIANAPOLIS · Eli Lilly press release, 30 Sep 2026, on a phase 2b trial presented at EASD 2026 in Milan
An Icelandic pharmacy chain and a wholesaler report rising demand for insulin syringes, while customs tests found many seized peptide vials did not contain what their labels claimed. The health minister says no national data on peptide use exist.
REYKJAVIK · RÚV report, 24 Oct 2026, with Icelandic Customs seizure (2 Mar 2026) and laboratory results (23 Jul 2026)
A Yale led retrospective study of 60 heart failure patients with implanted pressure sensors found lower pulmonary artery pressure six months after starting semaglutide or tirzepatide, and fewer heart failure hospitalisations in the following year.
PHOENIX · Retrospective abstract presented at the HFSA Annual Scientific Meeting 2026, Phoenix, 9 to 12 Oct 2026, as reported by HCPLive on 11 Oct 2026
Japan's health ministry recirculated its June notice on GLP 1 and GIP/GLP 1 drugs after reports of ketosis related reactions in people using them for cosmetic or slimming purposes. It said a causal link is unknown.
TOKYO · Ministry of Health, Labour and Welfare notice of 14 Oct 2026, posted by the PMDA, with the Japan Society for the Study of Obesity statement of 3 Oct 2026
In a Novo Nordisk funded real world analysis of 194 adults who moved from weekly injections to the daily Wegovy pill, average weight fell another 4.1% over three months. The study had no control group and relied on telehealth records.
MILAN · Novo Nordisk press release, 30 Sep 2026, on the OCTANE analysis presented at EASD 2026 (LBA 59)
In the ZUPREME 1 phase 2 study, weekly petrelintide cut body weight by up to 9.8% at 28 weeks against 1.7% on placebo. Nausea was the most common side effect, and the drug was never tested against a GLP 1 medicine.
COPENHAGEN · The Lancet Diabetes and Endocrinology, ZUPREME 1 phase 2 trial report and linked comment, published online 29 Sep 2026
The American College of Obstetricians and Gynecologists advised against GLP 1 drugs in pregnancy and against their use while breastfeeding preterm infants or newborns. It said safety data remain too limited to call the drugs safe.
WASHINGTON · ACOG Practice Advisory on GLP-1 receptor agonists in pregnancy and lactation, with ACOG press release, 23 Oct 2026
An analysis of the TOGETHER trials found that adding tirzepatide to ixekizumab cut predicted 10 year cardiovascular risk by about 30% at week 36 in people with psoriatic disease and obesity. The figure is a risk score, not counted heart attacks.
VIENNA · EADV Congress 2026 abstract 4328 (Weber et al.), as reported by Healio on 21 Oct 2026; TOGETHER-PsO and TOGETHER-PsA phase 3b trials
South Korea's health ministry will inspect hospitals and clinics suspected of selling self injected obesity drugs on site in breach of the rule that doctors prescribe and pharmacists dispense. Violations can bring prison terms, fines or licence suspensions.
SEJONG · Ministry of Health and Welfare press release, 22 Oct 2026, reported by Korea Biomedical Review
The KRAS peptide vaccine from Elicio Therapeutics did not significantly extend disease free survival in AMPLIFY-7P, Nature Medicine reports. Strong T cell responders did better, a signal the company plans to use in designing a phase 3 trial.
BOSTON · Nature Medicine, AMPLIFY-7P randomised phase 2 trial report, published online 23 Oct 2026
Apothecary Pharma of Cary, North Carolina, recalled 22 lots of injectable tirzepatide it could not show were sterile. The FDA rated the recall Class II.
CARY, N.C. · FDA Enforcement Report, recall D-0036-2027, published 14 Oct 2026
Adults with type 1 diabetes and obesity who stopped semaglutide after the ADJUST-T1D trial lost a median 3.6 points of time in range within 12 weeks, a small post hoc study reports.
PHILADELPHIA · Diabetes, Obesity and Metabolism, ADJUST-T1D extension study, online 31 Aug 2026; presented at Breakthrough T1D congress, 9 to 11 Oct 2026
India's Subject Expert Committee asked Novo Nordisk for Indian absorption and clinical data and an account of SNAC levels before it advises on oral Wegovy. The same meeting cleared three Roche petrelintide trials.
NEW DELHI · CDSCO Subject Expert Committee (Endocrinology and Metabolism) recommendations, meeting of 23 Sep 2026, posted 19 Oct 2026
TikTok now shows no results for searches on several named peptides, The Verge confirmed, but the broad topic and published videos remain visible and the company has not explained the change.
NEW YORK · The Verge report by Richard Lawler, 20 Oct 2026; FDA compounding safety risks page
Heineken told British pubs that GLP 1 weight loss drugs could cut beer and cider sales and urged half pints and low alcohol options. Rivals see a smaller effect, and controlled data come mainly from a trial in alcohol use disorder.
LONDON · Heineken presentation to UK hospitality customers, reported by Reuters and The Guardian, 23 Oct 2026
With patent protection ending in markets such as India and Canada, manufacturers lined up their own semaglutide. Making a 31-amino-acid peptide at scale is not the same as copying a pill.
NEW DELHI · Company announcements and national patent records
Two trials can report weight loss of 20% and mean very different things. Five questions sort out most of the confusion.
PEPTIDE ZONE DESK · Peptide Zone explainer; trial reporting conventions
An oral version of Wegovy was approved in the US, making it the first tablet GLP-1 medicine for chronic weight management. Getting a peptide through the gut is the engineering story.
BAGSVÆRD, Denmark · Novo Nordisk announcement of FDA approval; OASIS 4 trial
Lilly's triple-hormone peptide, acting on GIP, GLP-1 and glucagon receptors, also eased knee pain in people with obesity and knee osteoarthritis.
INDIANAPOLIS · Eli Lilly announcement (TRIUMPH-4 topline)
Oral semaglutide did not slow the progression of early Alzheimer's disease compared with placebo, ending one of the most watched tests of GLP-1 drugs outside metabolism.
BAGSVÆRD, Denmark · Novo Nordisk company announcement (EVOKE and EVOKE+ topline)
Semaglutide became the second drug cleared in the US for MASH with moderate to advanced fibrosis, on the strength of liver biopsy results at 72 weeks.
SILVER SPRING, Md. · FDA approval; ESSENCE trial part 1 (NEJM, 2025)
Orforglipron hits the GLP-1 receptor without being a peptide at all. Its first phase 3 obesity result was solid but below the injectable peptides, and that gap is the story.
INDIANAPOLIS · Eli Lilly announcement (ATTAIN-1 topline)
Europe's pharmacovigilance committee concluded that non-arteritic anterior ischemic optic neuropathy is a very rare side effect of semaglutide medicines.
AMSTERDAM · European Medicines Agency, PRAC meeting highlights
The first randomised comparison of the two best-selling obesity peptides found more weight loss and a larger drop in waist size with tirzepatide.
MÁLAGA, Spain · SURMOUNT-5 (NEJM); European Congress on Obesity 2025
A peptide with a huge online following has no approved product, a regulator flag for compounding and a place on the anti-doping list. Here is how each of those came about.
PEPTIDE ZONE DESK · FDA bulk drug substance lists; WADA Prohibited List
Roche agreed to co-develop and co-commercialise Zealand Pharma's long-acting amylin analogue, one of the largest partnership payments yet for an obesity peptide still in mid-stage trials.
BASEL, Switzerland · Roche and Zealand Pharma joint announcement
With the shortage resolved, pharmacies that had been making copies of semaglutide got a fixed window to wind down. Tirzepatide had gone through the same step about two months earlier.
SILVER SPRING, Md. · FDA drug shortage list and statement to compounders
Ozempic is now approved to reduce the risk of worsening kidney disease, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
SILVER SPRING, Md. · FDA approval; FLOW trial (NEJM, 2024)
The agency extended the Zepbound label to moderate-to-severe obstructive sleep apnea in adults with obesity, the first approval of any drug for the condition.
SILVER SPRING, Md. · FDA announcement; SURMOUNT-OSA trials (NEJM, 2024)